Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856822 | 0.89 | MEN1 (0.55) | TDP1MMP13MEN1KMT2APOLB | |
| SCHEMBL2856587 | 0.84 | TDP1 (0.67) | TDP1MMP13MEN1KMT2APOLB | |
| SCHEMBL2860730 | 0.83 | MEN1 (0.49) | TDP1MMP13MEN1KMT2APOLB | |
| SCHEMBL2858452 | 0.82 | MEN1 (0.51) | TDP1MEN1KMT2APOLBHDAC6 | |
| SCHEMBL2878777 | 0.81 | KMT2A (0.54) | TDP1MMP13MEN1KMT2APOLB | |
| SCHEMBL2876638 | 0.81 | MEN1 (0.56) | TDP1MMP13MEN1KMT2APOLB | |
| SCHEMBL2851998 | 0.81 | MAPK14 (0.58) | TDP1MEN1KMT2APOLBHDAC6 | |
| SCHEMBL2863438 | 0.81 | MEN1 (0.56) | TDP1MMP13MEN1KMT2APOLB | |
| SCHEMBL2868684 | 0.80 | MAPK14 (0.61) | TDP1MMP13MEN1KMT2APOLB | |
| SCHEMBL13299320 | 0.80 | MEN1 (0.53) | TDP1MMP13MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2174931-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | NAAA, NAT1, SAT1 | TDP1 4171/4885MMP13 3106/4885MEN1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.